Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;2(8):e405-e414.
doi: 10.1016/S2666-5247(21)00091-4. Epub 2021 Jun 23.

Invasive mould disease in fatal COVID-19: a systematic review of autopsies

Brittany E Kula  1 , Cornelius J Clancy  2 , M Hong Nguyen  2 , Ilan S Schwartz  1
Affiliations
Review

Invasive mould disease in fatal COVID-19: a systematic review of autopsies

Brittany E Kula et al. Lancet Microbe. 2021 Aug.

Abstract

Invasive mould disease (IMD) might affect up to a third of critically ill patients with COVID-19. COVID-19-associated pulmonary aspergillosis (CAPA) is typically diagnosed on the basis of a combination of non-specific clinical, radiographical, and mycological findings, but whether most cases represent invasive disease is unresolved. We systematically reviewed autopsy series of three or more decedents with COVID-19 for evidence of IMD. We searched PubMed, Web of Science, OVID (Embase), and medRxiv for studies in English or French published from Jan 1, 2019, to Sept 26, 2020. We identified 1070 references, of which 50 studies met the criteria. These studies described autopsies from 677 decedents, with individual-level data for 443 decedents. The median age was 70·0 years (IQR 57·0-79·0). Of decedents with individual-level data, 133 (30%) had diabetes, 97 (22%) had pre-existing lung disease, and 27 (6%) had immunocompromising conditions. Of 548 decedents with such data, 320 (58%) received invasive mechanical ventilation; among 140 decedents for whom this was known, ventilation was for a median of 9·0 days (IQR 5·0-20·0). Treatment included immunomodulation in 60 decedents and antifungals in 50 decedents. Autopsy-proven IMD occurred in 11 (2%) of 677 decedents, including eight CAPA, two unspecified IMD, and one disseminated mucormycosis. Among 320 decedents who received mechanical ventilation, six (2%) had IMD. We conclude that IMD, including CAPA, is an uncommon autopsy finding in COVID-19.

PubMed Disclaimer

Conflict of interest statement

BEK has no competing interests. CJC reports grants and personal fees from Astellas and Merck, grants from Melinta and Cidara, personal fees from The Medicines Company, Cidara, Scynexis, Shinogi, Opex, Needham & Company, and other support from Merck and T2Biosystems, outside the submitted work. MHN reports grants from the Centers for Disease Control and Prevention, Astellas, and the National Institutes of Health during the conduct of this study. ISS reports personal fees from AVIR Pharma, outside the submitted work.

Figures

Figure 1
Figure 1
Flow diagram of the study selection
Figure 2
Figure 2
Geographical distribution of included decedents
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Maiese A, Manetti AC, La Russa R, et al. Autopsy findings in COVID-19-related deaths: a literature review. Forensic Sci Med Pathol. 2020 doi: 10.1007/s12024-020-00310-8. published online Oct 7. - DOI - PMC - PubMed
    1. Thompson GR, III, Cornely OA, Pappas PG, et al. Invasive aspergillosis as an under-recognized superinfection in COVID-19. Open Forum Infect Dis. 2020;7 - PMC - PubMed
    1. Hoenigl M. Invasive fungal disease complicating COVID-19: when it rains it pours. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa1342. published online Sept 5. - DOI - PMC - PubMed
    1. Armstrong-James D, Youngs J, Bicanic T, et al. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. Eur Respir J. 2020;56 - PMC - PubMed
    1. Verweij PE, Gangneux J-P, Bassetti M, et al. Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbe. 2020;1:e53–e55. - PMC - PubMed